The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C
Open accessAbstract
The extent of liver fibrosis is an important prognostic factor in patients infected with hepatitis C virus. Administration of a combination of interferon and ribavirin produces a superior viral clearance response rate than interferon alone. The effect of this combination regimen on hepatic fibrosis has not been established. To determine the impact of combination regimen or interferon alone on the progression of liver fibrosis we pooled individual data of 1,509 patients with pretreatment and post–treatment biopsies from 3 randomized trials. Fibrosis progression and regression rates between biopsies were calculated by the Kaplan–Meier method and by the fibrosis progression rate per year. The percentage of patients without significant fibrosis (stage 0 or 1) at 96 weeks was 68 ± 4% (mean ± SE) when treated by combination regimen for 48 weeks, 64 ± 4% by interferon alone for 48 weeks, 42 ± 7% by combination regimen for 24 weeks (lower than both 48–week regimens P < .001), and 24 ± 9% interferon alone for 24 weeks (lower than the combination regimen for 24 weeks; P = .02). Three factors were independently associated with fibrosis reduction: sustained viral response, duration of treatment, and baseline fibrosis stage (all P < .001 in proportional hazards regression model). These results show that interferon and ribavirin combination therapy significantly reduces the rate of fibrosis progression in patients with hepatitis C. This effect was most prominent in patients who achieved a virologic response, those receiving 48 weeks of therapy, and in patients with significant fibrosis at baseline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Self-citationKnodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Self-citationNatural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Self-citationBedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Self-citationDavis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Self-citationClinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
Alter, M. J. (1997) · Hepatology · doi:10.1002/hep.510260711 · Cited by 1,075
Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., & Maertens, G. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-6-1093 · Cited by 685
Cited by
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Self-citationDavis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Self-citationProjecting future complications of chronic hepatitis C in the United States
Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50073 · Cited by 576
Self-citationBenvegnù, L., Gios, M., Boccato, S., & Alberti, A. (2004) · Gut · doi:10.1136/gut.2003.020263 · Cited by 454
Metadata
- Authors
- Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J.
- Venue
- Hepatology
- Published
- 2000-11
- Volume
- 32
- Issue
- 5
- Pages
- 1131-1137
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1999092338
- Cited by
- 280
- References
- 22
- FWCI
- 20.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. https://app.cochat.ai/papers/10.1053/jhep.2000.19347
- The paper
- Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J. (2000). Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. Hepatology. https://doi.org/10.1053/jhep.2000.19347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.